#USA #Sunnyvale #Cepheid #IVDR #Xpert Respiratory

Cepheid Secures CE Mark for Xpert® Respiratory Panel

In a significant development, Cepheid, a subsidiary of Danaher Corporation, has announced that it has successfully obtained the CE mark for its Xpert® Respiratory Panel. This noteworthy achievement aligns with the In Vitro Diagnostic Regulation (IVDR), which sets stringent standards for medical devices used for diagnostics. Available from November 10, 2026, this innovative test is designed to detect 13 common respiratory pathogens using just a single nasopharyngeal swab sample.

Improving Respiratory Infection Diagnosis

The Xpert® Respiratory Panel offers healthcare providers an effective tool to diagnose respiratory infections, a major public health challenge characterized by overlapping symptoms such as fever, cough, and sore throat. Each year, these infections result in significant morbidity in Europe, with flu outbreaks accounting for up to 50 million symptomatic cases and between 15,000 to 70,000 deaths. The test is vital for vulnerable populations, including children, the elderly, and immunocompromised individuals, who are at greater risk of severe complications and hospitalization due to respiratory infections.

The Importance of Identifying Pathogens

Accurate identification of pathogens is crucial for guiding clinical evaluations and enhancing patient management. Coinfections caused by viral and bacterial pathogens can lead to more severe illness and adverse outcomes. The Xpert® Respiratory Panel improves diagnostics by allowing clinicians to understand the underlying viral and bacterial infections better, facilitating informed therapeutic decision-making and responsible antibiotic use. This capability supports public health initiatives aimed at managing respiratory illnesses more effectively while minimizing unnecessary antibiotic prescriptions.

Features of the Xpert® Respiratory Panel

This advanced panel detects a range of pathogens: Adenovirus, coronavirus, SARS-CoV-2, Human metapneumovirus, Human rhinovirus/enterovirus, Human parainfluenza, Influenza A and B, Respiratory syncytial virus, Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae, and Chlamydia pneumoniae. By addressing both viral infections and bacterial colonization, clinicians are empowered to implement appropriate treatment plans tailored to individual patients.

Streamlining Diagnostic Processes

The ease of workflow with the Xpert® Respiratory Panel is another significant advantage. It incorporates a straightforward operational structure, requiring less than one minute of hands-on time and providing near-instant results under demand. This rapid turnaround can substantially improve patient care within hospital settings and outpatient facilities.

As healthcare systems brace for upcoming respiratory illness seasons, the capacity to allocate the appropriate test to the right patient is increasingly vital. Cepheid's development of this panel reinforces its range of respiratory solutions, which includes tests of varying complexity operating on existing GeneXpert® systems.

“By empowering clinicians to choose the right test for the right patient, the Xpert® Respiratory Panel enhances our suite of respiratory solutions, combining the flexibility of single-pathogen tests with broader syndromic panels,” said Christoph Martinaud, Senior Director of Medical Affairs for the EMEA region at Cepheid.

Conclusion

Cepheid’s commitment to innovation in molecular diagnostics is evident in its efforts to enhance patient outcomes through the Xpert® Respiratory Panel. As the company continues to streamline diagnostic processes, it ultimately aims to provide healthcare professionals with the tools needed to effectively deal with respiratory infections, thus improving clinical decision-making and patient health in real-time. For more details on this and additional Cepheid diagnostic solutions, visit www.cepheid.com.